Centocor deals boosts Johnson & Johnson's cardiac business
This article was originally published in Clinica
Johnson & Johnson is to buy US biotechnology company Centocor in a stock swap worth $4.9 billion. The deal comes two months after the failure of an earlier merger attempt between the two companies. Shares in Centocor rose around 16% to $57.56 on the news.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.